Is the incidence and prevalence of inhibitors greater with recombinant products? Yes

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

In summary, it is unlikely that in the near future we will have sufficient prospective randomized studies to resolve definitively the dilemma of inhibitor induction. Therefore, both physicians and patients need to recognize that choosing a recombinant therapeutic product may well increase the risk of this major complication of therapy.

Original languageEnglish
Pages (from-to)861-862
Number of pages2
JournalJournal of Thrombosis and Haemostasis
Volume2
Issue number6
DOIs
StatePublished - Jun 2004

Fingerprint

Dive into the research topics of 'Is the incidence and prevalence of inhibitors greater with recombinant products? Yes'. Together they form a unique fingerprint.

Cite this